APOE and Alzheimer disease: Three trials suggested that: serum DHA may be inversely correlated with brain amyloid PET, regardless of ApoE ε4 status [(157), Figure 1]; DHA supplementation may significantly decrease levels of blood Aβ42 [(158), Table 3]; and vitamin D supplementation may significantly reduce plasma Aβ42, alongside BACE1 and APP levels, [(159), Figure 1, Table 4] in patients with AD.